Quantification of intracellular λ light chain retained in treated myeloma cell lines
. | Experiment 1 . | . | Experiment 2 . | . | Experiment 3 . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| Ratio . | 8226/S . | MM.1S . | 8226/S . | MM.1S . | 8226/S . | MM.1S . | |||
| BZ/UNTX | 0.257 | 0.854 | 0.481 | 1.387 | 0.304 | 1.316 | |||
| BfA/UNTX | 2.208 | 1.517 | 1.908 | 1.470 | 2.603 | 1.402 | |||
. | Experiment 1 . | . | Experiment 2 . | . | Experiment 3 . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| Ratio . | 8226/S . | MM.1S . | 8226/S . | MM.1S . | 8226/S . | MM.1S . | |||
| BZ/UNTX | 0.257 | 0.854 | 0.481 | 1.387 | 0.304 | 1.316 | |||
| BfA/UNTX | 2.208 | 1.517 | 1.908 | 1.470 | 2.603 | 1.402 | |||
The 8226/S and MM.1S myeloma cell lines were left untreated, treated with 10 (MM.1S) to 100 nM (8226/S) bortezomib (BZ), or treated with 1 μM brefeldin A (BfA). Cell lysates were prepared after 7 hours of treatment, and 500 ng total protein was used to determine the amount of intracellular λ light chain present by ELISA. Three independent experiments are shown with the data presented as the ratio of the treated cells (BZ or BfA) to the untreated controls.